دورية أكاديمية
أعرض في EDS

Epidemiology of occult hepatitis B and C in Africa: A systematic review and meta-analysis.

التفاصيل البيبلوغرافية
العنوان: Epidemiology of occult hepatitis B and C in Africa: A systematic review and meta-analysis.
المؤلفون: Ondigui JLN; Department of Microbiology, The University of Yaounde I, Yaounde, Cameroon; Molecular Biology Laboratory, Chantal Biya International Reference Centre for AIDS Research (CIRCB), Yaounde, Cameroon., Kenmoe S; Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon. Electronic address: sebastien.kenmoe@ubuea.cm., Kengne-Ndé C; Epidemiological Surveillance, Evaluation and Research Unit, National AIDS Control Committee, Douala, Cameroon., Ebogo-Belobo JT; Medical Research Centre, Institute of Medical Research and Medicinal Plants Studies, Yaounde, Cameroon., Takuissu GR; Centre for Food, Food Security and Nutrition Research, Institute of Medical Research and Medicinal Plants Studies, Yaounde, Cameroon., Kenfack-Momo R; Department of Biochemistry, The University of Yaounde I, Yaounde, Cameroon., Mbaga DS; Department of Microbiology, The University of Yaounde I, Yaounde, Cameroon., Tchatchouang S; Scientific Direction, Centre Pasteur of Cameroon, Yaounde, Cameroon., Kenfack-Zanguim J; Department of Biochemistry, The University of Yaounde I, Yaounde, Cameroon., Fogang RL; Department of Animal Biology, University of Dschang, Dschang, Cameroon., Menkem EZ; Department of Biomedical Sciences, University of Buea, Buea, Cameroon., Kame-Ngasse GI; Medical Research Centre, Institute of Medical Research and Medicinal Plants Studies, Yaounde, Cameroon., Magoudjou-Pekam JN; Department of Biochemistry, The University of Yaounde I, Yaounde, Cameroon., Bowo-Ngandji A; Department of Microbiology, The University of Yaounde I, Yaounde, Cameroon., Goumkwa NM; Molecular Biology Laboratory, Chantal Biya International Reference Centre for AIDS Research (CIRCB), Yaounde, Cameroon., Esemu SN; Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon., Ndip L; Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon., Essama SHR; Department of Microbiology, The University of Yaounde I, Yaounde, Cameroon., Torimiro J; Molecular Biology Laboratory, Chantal Biya International Reference Centre for AIDS Research (CIRCB), Yaounde, Cameroon.
المصدر: Journal of infection and public health [J Infect Public Health] 2022 Dec; Vol. 15 (12), pp. 1436-1445. Date of Electronic Publication: 2022 Nov 12.
نوع المنشور: Meta-Analysis; Systematic Review; Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 101487384 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1876-035X (Electronic) Linking ISSN: 18760341 NLM ISO Abbreviation: J Infect Public Health Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford : Elsevier, 2008-
مواضيع طبية MeSH: Carcinoma, Hepatocellular* , Liver Neoplasms* , Hepatitis B*/epidemiology, Humans ; Liver Cirrhosis ; Africa/epidemiology
مستخلص: Background: Occult hepatitis B (OBI) and C (OCI) infections lead to hepatic crises including cases of liver cirrhosis and even hepatocellular carcinoma (HCC). OBI and OCI also pose a significant problem of their transmissibility. This study aimed to assess the overall prevalence of OBI and OCI in the African continent, a region highly endemic for classical hepatitis B and C viruses.
Methods: For this systematic review and meta-analysis, we searched: PubMed, Web of Science, African Journal Online and African Index Medicus for published studies on the prevalence of OBI and OCI in Africa. Study selection and data extraction were performed by at least two independent investigators. Heterogeneity (I²) was assessed using the χ² test on the Cochran Q statistic and H parameters. Sources of heterogeneity were explored by subgroup analyses. This study was registered in PROSPERO, with reference number CRD42021252772.
Results: We obtained 157 prevalence data for this meta-analysis, from 134 studies for OBI prevalence; 23 studies on OCI prevalence, and a single study on the OBI case fatality rate. The overall estimate for the prevalence of OBI was 14.8% [95% CI = 12.2-17.7] among 18579 participants. The prevalence of seronegative OBI and seropositive OBI was 7.4% [95% CI = 3.8-11.8] and 20.0% [95% CI = 15.3-25.1] respectively. The overall estimate for the prevalence of OCI was 10.7% [95% CI = 6.6-15.4] among 2865 participants. The pooled prevalence of seronegative OCI was estimated at 10.7% [95%CI = 4.8-18.3] and that of seropositive OCI at 14.4% [95%CI = 5.2-22.1]. In Sub-group analysis, patients with malignancies, chronic hepatitis C, and hemodialysis had a higher OCI prevalence. While those with malignancies, liver disorders, and HIV positive registered highest OBI prevalence.
Conclusion: This review shows a high prevalence of OBI and OCI in Africa, with variable prevalence between countries and population groups.
Competing Interests: Competing interests None.
(Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
References: J Med Virol. 2010 Sep;82(9):1569-75. (PMID: 20648611)
Infez Med. 2018 Sep 1;26(3):237-243. (PMID: 30246766)
Mediterr J Hematol Infect Dis. 2018 Jan 01;10(1):e2018007. (PMID: 29326804)
J Egypt Public Health Assoc. 2013 Apr;88(1):14-8. (PMID: 23528527)
J Int AIDS Soc. 2014 May 22;17:18871. (PMID: 24855985)
Control Clin Trials. 1986 Sep;7(3):177-88. (PMID: 3802833)
Clin Exp Med. 2022 Jan 23;:. (PMID: 35066710)
Virol J. 2015 Sep 30;12:153. (PMID: 26420301)
J Clin Transl Hepatol. 2017 Dec 28;5(4):319-326. (PMID: 29226098)
Sci Rep. 2018 Jan 26;8(1):1661. (PMID: 29374178)
J Med Virol. 2016 Apr;88(4):674-80. (PMID: 26334654)
Res Synth Methods. 2016 Mar;7(1):55-79. (PMID: 26332144)
Antivir Ther. 2010;15(7):1029-34. (PMID: 21041918)
J Viral Hepat. 2022 May;29(5):317-329. (PMID: 35253969)
World J Gastroenterol. 2015 Nov 14;21(42):11941-53. (PMID: 26576083)
Virol J. 2011 Mar 03;8:90. (PMID: 21371325)
J Gastroenterol Hepatol. 2008 Sep;23(9):1426-30. (PMID: 18853999)
World J Hepatol. 2017 Mar 28;9(9):477-486. (PMID: 28396718)
J Hepatol. 2007 Jan;46(1):160-70. (PMID: 17112622)
PLoS Med. 2009 Jul 21;6(7):e1000097. (PMID: 19621072)
Int J Infect Dis. 2014 Dec;29:65-70. (PMID: 25449238)
Transfus Med. 2008 Feb;18(1):55-61. (PMID: 18279193)
J Med Virol. 2009 Mar;81(3):406-12. (PMID: 19152393)
J Viral Hepat. 2020 Apr;27(4):415-427. (PMID: 31834645)
Virol J. 2020 Nov 13;17(1):176. (PMID: 33187530)
J Viral Hepat. 2014 Mar;21(3):153-62. (PMID: 24438677)
PLoS One. 2020 May 28;15(5):e0233727. (PMID: 32463824)
Infect Drug Resist. 2022 Feb 24;15:619-630. (PMID: 35241914)
J Infect Public Health. 2016 Jul-Aug;9(4):452-7. (PMID: 26778093)
Ther Adv Infect Dis. 2019 May 23;6:2049936119851464. (PMID: 31205689)
J Clin Virol. 2006 Jan;35(1):14-20. (PMID: 15916918)
Int J Infect Dis. 2009 Jul;13(4):488-92. (PMID: 19081280)
Scand J Gastroenterol. 2020 Aug;55(8):963-969. (PMID: 32649843)
Egypt J Immunol. 2017 Jan;24(1):131-142. (PMID: 29120585)
J Med Virol. 2016 Aug;88(8):1388-93. (PMID: 26743014)
Electron Physician. 2015 Dec 20;7(8):1619-25. (PMID: 26816589)
Arch Virol. 2017 Jan;162(1):63-69. (PMID: 27665588)
Hum Vaccin Immunother. 2014;10(8):2336-41. (PMID: 25424940)
J Clin Epidemiol. 2012 Sep;65(9):934-9. (PMID: 22742910)
PLoS One. 2016 Jan 14;11(1):e0143869. (PMID: 26764909)
J Hepatol. 2014 Mar;60(3):508-14. (PMID: 24211737)
Carcinogenesis. 2012 Jun;33(6):1219-24. (PMID: 22759751)
Diagnostics (Basel). 2022 Apr 17;12(4):. (PMID: 35454063)
PLoS One. 2022 May 31;17(5):e0269250. (PMID: 35639675)
Infect Dis (Lond). 2022 Dec;54(12):881-896. (PMID: 36047593)
Pan Afr Med J. 2013;14:44. (PMID: 23560127)
Mem Inst Oswaldo Cruz. 2020 Sep 23;115:e200006. (PMID: 32997000)
Eur J Gastroenterol Hepatol. 2021 Jul 1;33(7):1009-1014. (PMID: 33731578)
AIDS Res Ther. 2017 Mar 8;14(1):11. (PMID: 28270215)
J Clin Virol. 2015 Feb;63:12-7. (PMID: 25600597)
Egypt J Immunol. 2018 Jan;25(1):45-56. (PMID: 30242997)
J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):174-82. (PMID: 23892239)
Int J Infect Dis. 2012 Apr;16(4):e268-72. (PMID: 22305987)
J Viral Hepat. 2015 Feb;22(2):103-11. (PMID: 24754376)
J Infect Dis. 2022 Sep 13;226(5):862-870. (PMID: 34160616)
Vaccine. 2016 Jul 19;34(33):3835-9. (PMID: 27265453)
J Trop Med. 2014;2014:796121. (PMID: 24868208)
World J Hepatol. 2013 Feb 27;5(2):64-73. (PMID: 23646231)
PLoS One. 2018 Jan 9;13(1):e0190592. (PMID: 29315352)
Liver Int. 2009 Apr;29(4):518-24. (PMID: 19192168)
Virol J. 2010 Nov 17;7:324. (PMID: 21083926)
Environ Sci Pollut Res Int. 2018 Feb;25(6):5459-5464. (PMID: 29214477)
Arch Virol. 2020 Jan;165(1):33-42. (PMID: 31630275)
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420961202. (PMID: 33045856)
SAGE Open Med. 2022 Jan 30;10:20503121211072748. (PMID: 35127096)
Rev Soc Bras Med Trop. 2015 May-Jun;48(3):258-64. (PMID: 26108002)
Arch Inst Pasteur Tunis. 2010;87(1-2):17-24. (PMID: 21604457)
World J Hepatol. 2021 Feb 27;13(2):242-260. (PMID: 33708353)
PLoS One. 2021 Jan 6;16(1):e0244947. (PMID: 33406137)
BMJ. 1997 Sep 13;315(7109):629-34. (PMID: 9310563)
Med Mal Infect. 2018 May;48(3):175-179. (PMID: 29249466)
Eur J Gastroenterol Hepatol. 2019 Jun;31(6):716-722. (PMID: 30870221)
Infection. 2015 Jun;43(3):307-14. (PMID: 25665956)
Eur J Intern Med. 2011 Apr;22(2):187-90. (PMID: 21402251)
World J Methodol. 2022 May 20;12(3):179-190. (PMID: 35721241)
Int J Mol Sci. 2022 Jun 10;23(12):. (PMID: 35742931)
Hepat Res Treat. 2012;2012:429784. (PMID: 23304473)
East Mediterr Health J. 2017 Jul 16;23(5):329-334. (PMID: 28730585)
Iran Red Crescent Med J. 2015 Nov 29;17(11):e34181. (PMID: 26734487)
JGH Open. 2020 Aug 26;4(5):800-807. (PMID: 33102748)
Sci Rep. 2020 Dec 17;10(1):22182. (PMID: 33335238)
PLoS One. 2018 Jan 10;13(1):e0190775. (PMID: 29320552)
J Clin Transl Hepatol. 2018 Jun 28;6(2):155-160. (PMID: 29951360)
J Clin Microbiol. 2011 Jan;49(1):298-306. (PMID: 21048009)
Open Forum Infect Dis. 2017 Sep 13;4(4):ofx195. (PMID: 29062862)
Lancet. 1988 Dec 3;2(8623):1273-6. (PMID: 2904005)
Immunol Invest. 2010 Jan;39(3):284-91. (PMID: 20380524)
J Infect Public Health. 2017 Nov - Dec;10(6):761-765. (PMID: 28196636)
J Gastroenterol. 2009;44(4):359-64. (PMID: 19271112)
Curr Opin Virol. 2017 Jun;24:31-37. (PMID: 28419938)
Arab J Gastroenterol. 2018 Sep;19(3):101-105. (PMID: 30245116)
Clin Lab. 2012;58(9-10):1057-61. (PMID: 23163124)
Liver Int. 2014 Jul;34(6):e144-50. (PMID: 24502524)
Gut. 2005 May;54(5):682-5. (PMID: 15831916)
S Afr Med J. 2012 Feb 23;102(3 Pt 1):157-62. (PMID: 22380911)
Pan Afr Med J. 2021 Jul 06;39:175. (PMID: 34584601)
Genes (Basel). 2018 May 17;9(5):. (PMID: 29772814)
J Med Virol. 2015 Feb;87(2):213-21. (PMID: 25156907)
Transfusion. 2009 Apr;49(4):757-64. (PMID: 19171000)
J Hepatol. 2019 Aug;71(2):397-408. (PMID: 31004683)
Pathogens. 2021 Dec 17;10(12):. (PMID: 34959588)
PLoS One. 2015 Jul 06;10(7):e0131912. (PMID: 26148052)
Niger Med J. 2019 Jan-Feb;60(1):22-26. (PMID: 31413431)
Virologie (Montrouge). 2008 Apr 1;12(2):87-94. (PMID: 36131428)
East Mediterr Health J. 2014 Mar 13;20(2):130-8. (PMID: 24945562)
S Afr Med J. 2013 May;103(5):330-3. (PMID: 23971125)
World J Hepatol. 2012 Jul 27;4(7):218-23. (PMID: 22855697)
Int J Infect Dis. 2020 Mar;92:13-18. (PMID: 31863879)
Virol J. 2016 May 05;13:76. (PMID: 27150469)
Hepat Mon. 2012 Apr;12(4):253-8. (PMID: 22690232)
J Egypt Public Health Assoc. 2013 Apr;88(1):8-13. (PMID: 23528526)
J Med Virol. 2015 Mar;87(3):424-7. (PMID: 25185940)
Arch Basic Appl Med. 2018 Feb;6(1):87-93. (PMID: 29963604)
Virol J. 2022 Mar 24;19(1):53. (PMID: 35331278)
J Infect Public Health. 2015 Nov-Dec;8(6):562-9. (PMID: 26026236)
PLoS One. 2020 Nov 19;15(11):e0242577. (PMID: 33211768)
J Med Virol. 2009 Nov;81(11):1860-8. (PMID: 19774687)
Egypt J Immunol. 2017 Jan;24(1):37-48. (PMID: 29120576)
Int J Infect Dis. 2020 Aug;97:126-130. (PMID: 32497807)
PLoS One. 2012;7(10):e45750. (PMID: 23049685)
J Pediatr Hematol Oncol. 2021 Jan;43(1):e45-e50. (PMID: 32769568)
Infect Drug Resist. 2019 Jan 22;12:273-279. (PMID: 30774394)
Intervirology. 2009;52(3):123-31. (PMID: 19468235)
Virologie (Montrouge). 2005 Aug 1;9(4):331. (PMID: 34679301)
Int J Oncol. 2013 Apr;42(4):1459-65. (PMID: 23404231)
World J Gastroenterol. 2012 Jun 21;18(23):2887-94. (PMID: 22736911)
J Med Virol. 2015 Mar;87(3):388-400. (PMID: 25164924)
J Infect Dev Ctries. 2012 Apr 13;6(4):340-6. (PMID: 22505444)
Curr HIV Res. 2016;14(2):165-71. (PMID: 26419862)
Blood Transfus. 2019 Nov;17(6):403-408. (PMID: 31846605)
J Med Virol. 2011 Jun;83(6):929-34. (PMID: 21503902)
فهرسة مساهمة: Keywords: Africa; Occult hepatitis B; Occult hepatitis C; Prevalence
تواريخ الأحداث: Date Created: 20221117 Date Completed: 20221206 Latest Revision: 20221206
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7613883
DOI: 10.1016/j.jiph.2022.11.008
PMID: 36395668
قاعدة البيانات: MEDLINE
الوصف
تدمد:1876-035X
DOI:10.1016/j.jiph.2022.11.008